No Data
Is CRISPR Therapeutics AG (CRSP) the Best Stock to Buy and Hold for 5 Years?
Guggenheim Assumes CRISPR Therapeutics at Neutral
Guggenheim analyst Debjit Chattopadhyay assumes CRISPR Therapeutics with a Neutral rating.
Guggenheim Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating
Guggenheim analyst Debjit Chattopadhyay initiates coverage on $CRISPR Therapeutics(CRSP.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 45.2% and a total average
Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28
Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new tr
CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon?